Dry Eye Syndrome Market Size & Outlook, 2025-2033

Dry Eye Syndrome Market Size

The global dry eye syndrome market size was valued at USD 7.30 billion in 2024 and is projected to grow from USD 7.81 billion in 2025 to reach USD 13.34 billion by 2033, exhibiting a CAGR of 6.92% during the forecast period (2025–2033). 

Dry eye syndrome (DES) is a multifactorial ocular condition characterised by tear film instability, leading to discomfort and visual disturbances. The increasing prevalence of DES is attributed to factors such as ageing populations, prolonged screen time, environmental pollution, and post-surgical complications. The global dry eye syndrome (DES) market is experiencing steady growth, driven by the increasing prevalence of digital device usage, environmental pollution, and an ageing population. Prolonged screen time reduces blink rates, leading to tear film instability and ocular discomfort. Environmental factors like air pollution and dry climates exacerbate these symptoms. Additionally, the rise in autoimmune disorders and post-surgical complications contributes to the growing incidence of DES. Advancements in diagnostic tools and treatment options, including anti-inflammatory drugs and artificial tears, enhance patient outcomes. The market also benefits from increased awareness and healthcare spending, particularly in North America, which held over 55% of the market share in 2024.

Dry Eye Syndrome Market Trend

Technological Advancements in Treatment

The Dry Eye Syndrome (DES) market is undergoing a wave of technological innovations to improve treatment efficacy and patient adherence. Notable advancements include the development of preservative-free formulations, enhanced drug delivery systems, and introduction devices that target the root causes of DES. Additionally, devices like TearCare and iLux, which use targeted thermal pulsation therapy, are transforming how meibomian gland dysfunction (MGD), a leading cause of evaporative dry eye, is treated. These devices provide non-invasive treatment options, offering convenience and improving patient compliance compared to traditional treatments like eye drops. 

• For instance, in December 2024, Israel-based Novoxel announced the FDA clearance of its Tixel device to applylocalised heat and pressure for patients who have evaporative dry eye disease due to meibomian gland dysfunction (MGD). 

As technology advances, the market is expected to evolve, improving treatment options and accessibility for patients worldwide.

To get more insights about this report Download Free Sample Report

Dry Eye Syndrome Market Growth Factors

Rising Prevalence of Dry Eye Syndrome

The increasing prevalence of Dry Eye Syndrome (DES) has emerged as a key driver in the market's growth. According to the World Health Organisation, approximately 300 million people globally suffer from this condition, with the ageing population particularly at risk. Factors such as the widespread use of digital devices contribute to the rise of DES, which increases screen time and contributes to digital eye strain. This phenomenon, known as "computer vision syndrome," is becoming more common with the growing reliance on smartphones, computers, and tablets. 

Additionally, increased awareness of the disease and its impact on quality of life has also spurred demand for more targeted treatments, further expanding the market. Companies like Allergan and Johnson & Johnson have responded to this surge by introducing new over-the-counter products to alleviate the discomfort associated with DES, and the growing focus on holistic eye health is expected to drive market growth in the coming years.

Market Restraining Factors

High Cost of Advanced Treatments

Despite the availability of various treatments, the high cost of advanced therapies remains a significant restraint on the growth of the Dry Eye Syndrome (DES) market. Prescription medications, such as Restasis (cyclosporine A) and Xiidra (lifitegrast), which aim to reduce eye inflammation, can be expensive, with monthly treatment costs sometimes exceeding $500. Additionally, the growing popularity of innovative devices like the LipiFlow Thermal Pulsation System, which costs over $2,000 per treatment session, presents affordability challenges for many patients. These high treatment costs can make advanced DES therapies inaccessible, especially in regions with lower healthcare spending or inadequate insurance coverage. 

Moreover, while devices like iLux and TearCare offer targeted relief, they require multiple sessions, contributing to a growing financial burden for patients who need regular treatments. This challenge is particularly pronounced in low- and middle-income countries, where the cost of healthcare and limited insurance options restrict access to these advanced solutions. With healthcare providers prioritising more cost-effective, accessible treatments, the high price point of cutting-edge therapies represents a significant barrier to widespread adoption, limiting the market's growth potential.

Market Opportunity

Expansion in Emerging Markets

Emerging markets, particularly in Asia-Pacific and Latin America, represent a major growth opportunity for the Dry Eye Syndrome (DES) market. These regions are seeing rapid urbanisation and industrialisation, which are leading to greater exposure to environmental pollutants, a significant contributor to the rise in DES cases. According to reports, the Asia-Pacific region is projected to grow at a robust compound annual growth rate (CAGR) due to increased pollution, the rising incidence of digital eye strain, and developing healthcare infrastructure. 

• For instance, in India and China, where urbanisation has been accompanied by increased vehicle emissions and industrial pollutants, DES cases have surged, prompting a rising demand for effective treatments. In response, companies like Alcon and Novartis have expanded their presence in these markets, launching region-specific products and forming strategic partnerships with local healthcare providers. As awareness of DES increases and more accessible treatments become available, the market is expected to see substantial growth in these emerging economies over the next few years.

Regional Insight

North America continues to dominate the global dry eye syndrome market, largely due to the high prevalence of the condition, advanced healthcare infrastructure, and substantial investments in research and development. In 2024, the North American market was valued at USD 2.8 billion and is projected to grow to USD 4.4 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 4.89%. The prevalence of dry eye disease is particularly high in the U.S., where an ageing population, widespread digital device usage, and environmental factors such as air pollution and dry climates contribute to the increasing number of cases. Moreover, the high level of awareness about dry eye syndrome and the availability of prescription and over-the-counter treatment options have spurred market growth. Government initiatives, such as funding from the National Eye Institute, which supports vision-related research, further expand the market. 

United States Dry Eye Syndrome Market Trends

The United States is the dominant player in the global dry eye syndrome (DES) market, fueled by a high incidence of dry eye disease, widespread digital device usage, and an aging population. Advanced diagnostic technologies, high treatment adoption rates, and significant R&D spending drive continuous innovation. Companies like AbbVie (Refresh) and Bausch + Lomb (Xiidra) are expanding product lines, with ongoing clinical trials exploring long-term therapies and AI-based diagnostic tools. Increasing awareness campaigns by the American Academy of Ophthalmology and insurance support for new therapies further strengthen the market.

• Canada’s DES market is experiencing steady growth due to increasing screen time, environmental factors, and proactive healthcare policies. The country's publicly funded healthcare system ensures broader access to diagnosis and treatment, reducing the financial burden on patients. Partnerships between research institutions such as the University of Toronto and global pharmaceutical companies result in innovative clinical trials and emerging therapies. Companies like Aequus Pharmaceuticals are introducing preservative-free formulations tailored for chronic use, expanding treatment options for Canadian patients.

Asia Pacific Dry Eye Syndrome Market Trends

The Asia-Pacific region is poised to become the fastest-growing market for dry eye syndrome due to a combination of factors, including rapid industrialisation, increasing digital screen usage, and an ageing population. Countries like China and India are experiencing a significant surge in dry eye cases, particularly as urbanisation leads to increased exposure to environmental pollutants. At the same time, the use of digital devices continues to grow. In China, the regulatory approval for clinical trials of new dry eye treatments, such as BRM421 by BRIM Biotechnology, demonstrates the increasing investment in novel therapies for the condition. Additionally, the government’s efforts to improve healthcare infrastructure and the rising awareness about eye health drive the demand for better diagnosis and treatment. As more patients seek solutions for managing dry eye disease, pharmaceutical companies focus on expanding their regional presence through strategic partnerships and localised offerings. 

China Dry Eye Syndrome Market Trends

China is witnessing exponential growth in its DES market due to rapid industrialisation, rising air pollution levels, extensive use of digital devices, and an ageing population. Government policies under the “Healthy China 2030” initiative encourage investment in healthcare infrastructure and innovation. Local companies like China Pharma Holdings and Shenyang Xingqi Pharmaceutical are launching novel delivery systems and treatment devices tailored to urban populations. E-commerce expansion is also enhancing accessibility to over-the-counter DES products nationwide.

• India’s DES market is poised for accelerated growth due to its massive population, greater screen exposure among younger demographics, and heightened awareness of ocular health. Increased urbanisation, coupled with rising pollution levels, is contributing to a growing number of DES diagnoses. Government initiatives under Ayushman Bharat and increased public-private partnerships are improving access to specialised eye care in rural and semi-urban areas. 

Europe Dry Eye Syndrome Market Trends

Europe is experiencing notable dry eye syndrome market growth, driven by an aging population, increasing screen time, and environmental pollution. In countries like the UK, Germany, and France, rising cases of dry eye disease have prompted greater demand for effective treatments. Government support for healthcare innovation and reimbursement policies also plays a key role in the region's market expansion. The European market is seeing significant technological advances, such as integrating thermal pulsation therapies and new artificial tear formulations, offering patients improved treatment options. Furthermore, innovation-focused initiatives like EIT Health, a European Union-funded program, continue to support the development of novel technologies for eye disorders, with financial backing of up to EUR 1.5 million for projects like PeriVision and INVENTION. These initiatives are accelerating innovation, creating more efficient and accessible treatments. 

Uk Dry Eye Syndrome Market Trends

In the UK, approximately one-third of the population experiences symptoms of dry eye syndrome, making it a critical public health concern. Organisations like Théa UK lead public awareness campaigns and distribute innovative preservative-free eye care products. The rise in telemedicine services post-pandemic has also contributed to better management and diagnosis of DES. The UK is also a hub for clinical research, with universities such as UCL partnering with biotech firms to test novel delivery systems and nanotechnology-based eye drops, bolstering the market’s evolution.

• Germany’s dry eye syndrome market benefits from the nation’s strong pharmaceutical industry, high health standards, and emphasis on technological innovation. The country is home to Novaliq GmbH, a pioneering firm in water-free eye drop technologies, which has introduced EvoTears and partnered with Bausch + Lomb for global distribution. Germany’s advanced regulatory framework accelerates the approval process for novel therapies, while academic institutions like Charité – Universitätsmedizin Berlin are involved in extensive ocular research. The population’s ageing demographic and increasing screen use also increase DES cases.

Product Insights

Artificial tears hold the largest share in the dry eye syndrome market due to their accessibility, ease of use, and immediate symptomatic relief. These lubricating eye drops help restore moisture and reduce irritation caused by insufficient tear production or excessive tear evaporation. Artificial tears account for over 40% of the market revenue due to the increasing prevalence of dry eye syndrome worldwide, driven by aging populations, increased screen time, and environmental pollution. Their wide availability over the counter makes them a first-line treatment option, particularly for mild to moderate dry eye cases. Recent innovations include preservative-free formulations and enhanced viscosity agents that improve comfort and duration of effect. Market leaders like Santen and Bausch + Lomb continuously innovate artificial tears to improve patient adherence and outcomes. The global shift towards preventive and symptomatic management strongly supports the growth of this segment.

Distribution Channel Insights

Hospital pharmacies dominate the distribution channel for dry eye syndrome treatments, primarily due to their direct link with ophthalmologists and specialty clinics where diagnosis and prescriptions are made. Hospital pharmacies offer a wide range of products, including prescription anti-inflammatory drugs and punctal plugs requiring clinical oversight. Hospital pharmacies account for over 50% of the market share in this segment, driven by the increasing number of ophthalmic procedures and hospital visits for eye care. The rise in hospital-based outpatient clinics and integrated healthcare models further strengthens this channel. Hospitals’ ability to provide comprehensive care, including diagnostics, treatment, and follow-up, ensures high patient adherence. Moreover, government hospital programs and insurance reimbursements promote access to advanced dry eye therapies through hospital pharmacies, particularly in developed regions like North America and Europe.

Company Market Share

The DES market is highly competitive, with key players focusing on product innovation, strategic partnerships, and geographic expansion. These companies employ mergers and acquisitions, R&D investments, and collaborations to strengthen their market positions.

• AbbVie Inc.: AbbVie Inc. holds a significant share in the DES market, primarily through its acquisition of Allergan and the popular Refresh product line.The company's strong brand presence, extensive distribution network, and commitment to innovation have solidified its position in the market.AbbVie's focus on expanding its ophthalmology portfolio and investing in R&D ensures sustained growth in the DES segment.

List of key players in Dry Eye Syndrome Market

1. AbbVie Inc.
2. Alcon Inc.
3. Novartis AG
4. Santen Pharmaceutical Co., Ltd.
5. Johnson & Johnson Services, Inc.
6. Bausch Health Companies Inc.
7. Otsuka Pharmaceutical Co., Ltd.
8. Sun Pharmaceutical Industries Ltd.
9. OASIS Medical
10. Sentiss Pharma Pvt. Ltd.
11. AFT Pharmaceuticals
12. Oyster Point Pharma, Inc.
13. Ursapharm Arzneimittel GmbH
14. Mitotech S.A.
15. Scope Ophthalmics Ltd.

To get more findings about this report Download Market Share

Recent Developments

• May 2024- Novaliq and Laboratoires Théa announced the European Commission's approval of Vevizye, the first water-free ciclosporin 0.1% eye drop solution, for treating dry eye disease in adults.
• May 2024- Nordic Pharma launched Lacrifill Canalicular Gel, a crosslinked hyaluronic acid gel designed for canalicular occlusion, enhancing tear retention. Clinical trials demonstrated sustained improvements in Schirmer scores and Ocular Surface Disease Index (OSDI) over six months.